Robert J. Slack

Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis

T. Maher, P. Molyneaux, A. MacKinnon, 2020, European Respiratory Journal.

The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis

E. Sarchielli, L. Vignozzi, I. Cellai, 2024, Frontiers in pharmacology.

Defining the mechanism of galectin-3–mediated TGF-β1 activation and its role in lung fibrosis

F. Zetterberg, Panayiota Stylianou, R. G. Jenkins, 2023, bioRxiv.

Galectin-3: therapeutic targeting in liver disease

Massimo Pinzani, D. Tonev, A. C. Mackinnon, 2023, Expert opinion on therapeutic targets.